An Open Label Dose-Ranging Study in Healthy Male Subjects to Investigate the Binding Potential of JNJ-40411813 to Serotonin 2A Receptors in the Central Nervous System.
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2013
At a glance
- Drugs ADX 71149 (Primary)
- Indications Psychotic disorders
- Focus Pharmacokinetics
- 25 May 2011 New trial record